Cargando…

Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging

PURPOSE: To evaluate fluorine-18 fluorocholine (FCH) PET/CT for the detection of recurrent prostate cancer in relation to prostate-specific antigen (PSA) level. METHODS: FCH PET/CT was performed in 50 patients with rising PSA levels at follow-up of primary treatment of prostate cancer (radical prost...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwee, Sandi A., Coel, Marc N., Lim, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400027/
https://www.ncbi.nlm.nih.gov/pubmed/22549847
http://dx.doi.org/10.1007/s12149-012-0601-8
_version_ 1782238448882548736
author Kwee, Sandi A.
Coel, Marc N.
Lim, John
author_facet Kwee, Sandi A.
Coel, Marc N.
Lim, John
author_sort Kwee, Sandi A.
collection PubMed
description PURPOSE: To evaluate fluorine-18 fluorocholine (FCH) PET/CT for the detection of recurrent prostate cancer in relation to prostate-specific antigen (PSA) level. METHODS: FCH PET/CT was performed in 50 patients with rising PSA levels at follow-up of primary treatment of prostate cancer (radical prostatectomy in 28, radiation therapy in 13, and brachytherapy in 9). PET detection rates were determined at various PSA thresholds and examined by receiver operating characteristic analysis. RESULTS: Findings consistent with recurrent prostate cancer were noted on FCH PET/CT in 31/50 (62 %) patients, with positive findings in 17/18 (94 %), and 11/13 (85 %), 2/7 (29 %), and 1/12 (8 %) patients with PSA >4, >2–4, >0.5–2, and ≤0.5 ng/mL, respectively. These findings were indicative of local/regional recurrence in 23 cases and systemic recurrence in 8 cases, with only a single route of recurrence (i.e., either hematogenous, lymphatic, or intraprostatic) in 84 % of PET scans with positive findings. Abnormal tumor activity was detected in 88 % of patients with a PSA level of 1.1 ng/mL or higher, and in only 6 % of patients with a PSA level below this threshold value. CONCLUSION: FCH PET/CT may serve to identify the route of tumor progression in patients with recurrent prostate cancer; however, the likelihood of tumor detection may be related to the PSA level at the time of imaging.
format Online
Article
Text
id pubmed-3400027
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-34000272012-07-25 Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging Kwee, Sandi A. Coel, Marc N. Lim, John Ann Nucl Med Original Article PURPOSE: To evaluate fluorine-18 fluorocholine (FCH) PET/CT for the detection of recurrent prostate cancer in relation to prostate-specific antigen (PSA) level. METHODS: FCH PET/CT was performed in 50 patients with rising PSA levels at follow-up of primary treatment of prostate cancer (radical prostatectomy in 28, radiation therapy in 13, and brachytherapy in 9). PET detection rates were determined at various PSA thresholds and examined by receiver operating characteristic analysis. RESULTS: Findings consistent with recurrent prostate cancer were noted on FCH PET/CT in 31/50 (62 %) patients, with positive findings in 17/18 (94 %), and 11/13 (85 %), 2/7 (29 %), and 1/12 (8 %) patients with PSA >4, >2–4, >0.5–2, and ≤0.5 ng/mL, respectively. These findings were indicative of local/regional recurrence in 23 cases and systemic recurrence in 8 cases, with only a single route of recurrence (i.e., either hematogenous, lymphatic, or intraprostatic) in 84 % of PET scans with positive findings. Abnormal tumor activity was detected in 88 % of patients with a PSA level of 1.1 ng/mL or higher, and in only 6 % of patients with a PSA level below this threshold value. CONCLUSION: FCH PET/CT may serve to identify the route of tumor progression in patients with recurrent prostate cancer; however, the likelihood of tumor detection may be related to the PSA level at the time of imaging. Springer Japan 2012-05-02 2012-07 /pmc/articles/PMC3400027/ /pubmed/22549847 http://dx.doi.org/10.1007/s12149-012-0601-8 Text en © The Japanese Society of Nuclear Medicine 2012
spellingShingle Original Article
Kwee, Sandi A.
Coel, Marc N.
Lim, John
Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
title Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
title_full Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
title_fullStr Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
title_full_unstemmed Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
title_short Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
title_sort detection of recurrent prostate cancer with 18f-fluorocholine pet/ct in relation to psa level at the time of imaging
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400027/
https://www.ncbi.nlm.nih.gov/pubmed/22549847
http://dx.doi.org/10.1007/s12149-012-0601-8
work_keys_str_mv AT kweesandia detectionofrecurrentprostatecancerwith18ffluorocholinepetctinrelationtopsalevelatthetimeofimaging
AT coelmarcn detectionofrecurrentprostatecancerwith18ffluorocholinepetctinrelationtopsalevelatthetimeofimaging
AT limjohn detectionofrecurrentprostatecancerwith18ffluorocholinepetctinrelationtopsalevelatthetimeofimaging